Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Entheon ID(TM) Clinical Study to Assess the Effect of Ketamine on Neurological Activity as Measured by EEG

Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials

Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

Dr. David Erritzoe to provide guidance on psychopharmacological research

Entheon Biomedical Corp. Announces DTC Eligibility

Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

EEG Study to be incorporated into Entheon IQ(TM), developing data-driven treatment algorithms for psychedelic treatments

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols